310210.KQ
Voronoi, Inc.
KOE · Healthcare · Biotechnology · RO
KRW 147,200.00
−13.16%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.2B | 7.5B | — | — | 9.8B |
| Cost of Revenue | 1.2B | — | — | — | — |
| Gross Profit | 2.9B | 7.5B | — | — | 9.8B |
| Operating Expenses | |||||
| R&D Expense | 48.3B | 31.0B | 17.9B | 14.5B | 11.7B |
| SG&A Expense | 7.9B | 4.5B | 16.1B | 13.8B | 1.9B |
| General & Admin Expense | (4.4B) | 1.9B | 14.6B | 13.0B | 975.2M |
| Selling & Marketing Expense | 2.7B | 2.6B | 1.5B | 809.2M | 956.1M |
| Other Expenses | 35.7B | 26.4B | 15.7B | 14.9B | 14.0B |
| Total Operating Expenses | 84.0B | 61.9B | 34.0B | 28.3B | 27.6B |
| Cost and Expenses | 85.2B | 61.9B | 34.0B | 28.3B | 27.6B |
| Operating Income (EBIT) | (81.0B) | (54.4B) | (34.0B) | (31.3B) | (17.9B) |
| Non-Operating | |||||
| Interest Income | 3.4B | 2.0B | 1.9B | 1.1B | 315.7M |
| Interest Expense | 5.4B | 2.6B | 580.7M | 1.9B | 2.1B |
| Net Interest Income | (2.0B) | (685.7M) | 1.9B | (763.3M) | (1.8B) |
| Other Non-Op Income/Expense | 4.0B | 3.7B | 1.3B | (7.9B) | (1.6B) |
| Non-Operating Income (excl Interest) | (6.3B) | (6.4B) | 2.4B | (470.00) | (552.0M) |
| EBT (Pre-Tax Income) | (77.1B) | (50.6B) | (32.6B) | (36.2B) | (19.4B) |
| Income Tax Expense | (2.6B) | (2.6B) | (32.1M) | 695.8M | 464.9M |
| Bottom Line | |||||
| Net Income | (74.4B) | (48.0B) | (32.6B) | (36.8B) | (19.9B) |
| Earnings from Cont. Ops | (74.4B) | (48.0B) | (32.6B) | (36.8B) | (19.9B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (74.4B) | (48.0B) | (32.6B) | (36.8B) | (19.9B) |
| Per Share | |||||
| Basic EPS | (₩4,074) | (₩2,611) | (₩1,860) | (₩2,401) | (₩1,170) |
| Diluted EPS | (₩4,074) | (₩2,611) | (₩1,860) | (₩2,401) | (₩1,170) |
| Revenue Per Share | ₩227 | ₩408 | ₩0 | ₩0 | ₩574 |
| Shares | |||||
| Basic Shares Outstanding | 18.3M | 18.4M | 17.5M | 15.3M | 17.0M |
| Diluted Shares Outstanding | 18.3M | 18.4M | 17.5M | 15.3M | 17.0M |
| Profitability Metrics | |||||
| EBITDA | (78.0B) | (52.6B) | (34.4B) | (28.6B) | (14.3B) |
| D&A | 2.2B | 1.8B | 2.0B | 2.7B | 3.0B |
| EBIT | (80.2B) | (48.0B) | (36.3B) | (31.3B) | (17.3B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026